Dr. Raven Lin serves as CEO and Director of Pilatus Biosciences since 2023. With over 15 years of experience in the pharmaceutical industry, Dr. Lin has been involved in multiple first-in-class new drug developments. In addition, Dr. Lin has facilitated over $3 billion in business development & licensing transactions.

Dr. Ho serves as Chairperson of the scientific advisory board since 2022. Dr. Ho is a professor in the Department of Oncology, the University of Lausanne Ludwig Institute for Cancer Research, Switzerland. Dr. Ho excelled in the emerging field of immunometabolomics. His research explores the metabolic interactions between cancer and immune cells, aiming to enhance immunotherapy by manipulating this crosstalk.

With a distinguished career spanning entrepreneurial ventures, consulting at a Big 5 firm, and academia in banking, finance, and accounting, Prof. Dr. Minyue Dong brings extensive expertise across Asia, Europe, and North America in international management, global financial services, and business development, with a strong focus on life sciences and other high-tech innovations.

Jay Campbell has served as Interim US Site Head, Corporate Strategy & Development of Pilatus Biosciences since 2025.  Mr. Campbell has 12 years of life sciences investment banking experience, over 10 years of corporate experience at private/public oncology companies and has worked on 47 strategic and financing transactions and investments representing over $13.4 billion.

Mr. James Hsu has served as Director since 2025, representing Elixiron Immunotherapeutics. With over 15 years of experience in the financial industry, Mr. Hsu has managed several large-scale projects, including the Fubon Bank (China) merger and acquisition.

Lori McDermott has served as the Head of Clinical Operations for Pilatus Biosciences since 2025. Ms. McDermott has over 25 years of experience within clinical operations, the last 10 of which have been focused exclusively in early phase oncology. She has successfully overseen submission and clearance of multiple oncology INDs in CDER and CBER, with none resulting in clinical hold, and has managed early phase oncology programs and regulatory activities supporting FDA Fast Track and Orphan Drug designations.

30 years of insurance & financial services industries experience in strategy & business development, Operation & digital transformation.